1. Home
  2. BLNE vs ICU Comparison

BLNE vs ICU Comparison

Compare BLNE & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLNE
  • ICU
  • Stock Information
  • Founded
  • BLNE 2019
  • ICU 2018
  • Country
  • BLNE United States
  • ICU United States
  • Employees
  • BLNE N/A
  • ICU N/A
  • Industry
  • BLNE
  • ICU Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLNE
  • ICU Health Care
  • Exchange
  • BLNE NYSE
  • ICU Nasdaq
  • Market Cap
  • BLNE 11.9M
  • ICU 10.4M
  • IPO Year
  • BLNE N/A
  • ICU N/A
  • Fundamental
  • Price
  • BLNE $0.77
  • ICU $1.27
  • Analyst Decision
  • BLNE
  • ICU
  • Analyst Count
  • BLNE 0
  • ICU 0
  • Target Price
  • BLNE N/A
  • ICU N/A
  • AVG Volume (30 Days)
  • BLNE 737.4K
  • ICU 142.8K
  • Earning Date
  • BLNE 05-20-2025
  • ICU 05-14-2025
  • Dividend Yield
  • BLNE N/A
  • ICU N/A
  • EPS Growth
  • BLNE N/A
  • ICU N/A
  • EPS
  • BLNE N/A
  • ICU N/A
  • Revenue
  • BLNE $5,213,000.00
  • ICU $428,000.00
  • Revenue This Year
  • BLNE $456.73
  • ICU $754.07
  • Revenue Next Year
  • BLNE $28.26
  • ICU $100.09
  • P/E Ratio
  • BLNE N/A
  • ICU N/A
  • Revenue Growth
  • BLNE 63.03
  • ICU N/A
  • 52 Week Low
  • BLNE $0.76
  • ICU $1.11
  • 52 Week High
  • BLNE $29.80
  • ICU $13.85
  • Technical
  • Relative Strength Index (RSI)
  • BLNE N/A
  • ICU 51.67
  • Support Level
  • BLNE N/A
  • ICU $1.12
  • Resistance Level
  • BLNE N/A
  • ICU $1.34
  • Average True Range (ATR)
  • BLNE 0.00
  • ICU 0.07
  • MACD
  • BLNE 0.00
  • ICU 0.01
  • Stochastic Oscillator
  • BLNE 0.00
  • ICU 68.18

About BLNE EASTSIDE DISTILLING INC

Beeline Holdings Inc is a technology-driven mortgage lender and title provider building a fully digital, AI-powered platform that simplifies and accelerates the home financing process.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: